Difference between revisions of "Team:ASIJ Tokyo"
19andersonn (Talk | contribs) |
|||
| Line 37: | Line 37: | ||
letter-spacing: 15px; | letter-spacing: 15px; | ||
} | } | ||
| + | |||
| + | #stop { | ||
| + | color: red; | ||
| + | font-size: 200px; | ||
#red { | #red { | ||
| Line 106: | Line 110: | ||
<body> | <body> | ||
<div id="everything"> | <div id="everything"> | ||
| + | <p id="stop"> STOP EDITING THIS </p> | ||
<div id="banner"><img src="https://static.igem.org/mediawiki/2018/2/2d/T--ASIJ_Tokyo--teambanner.png" id="banner"></img></div> | <div id="banner"><img src="https://static.igem.org/mediawiki/2018/2/2d/T--ASIJ_Tokyo--teambanner.png" id="banner"></img></div> | ||
<div class="container topBotomBordersOut"> | <div class="container topBotomBordersOut"> | ||
Revision as of 04:52, 29 June 2018
STOP EDITING THIS
A1-AT
DELIVERY
A1AT deLIVERy - Using Stem Cell and CRISPR Technology to Combat Alpha-1 Antitrypsin Deficiency
ABSTRACT
Alpha-1 Antitrypsin deficiency is a common genetic disorder -- the defective gene for which is carried by 1 in 25 people -- which arises from a single base pair mutation in the SERPINA1 gene, resulting in the production of a form of antitrypsin prone to polymerization. The mutated antitrypsin then builds up in liver cells and is unable to inhibit proteases in the lungs, leading to damage in both. Using CRISPR-Cas9 technology, we aimed to fix the error in SERPINA1 so that proper antitrypsin can be produced. We will show proof of concept in E. Coli cells using osmy secretion tags and GFP as a reporter. We hope to design a liver organ bud using IPS cell technology to deliver function A1AT through collaboration with Dr. Kagimoto of Healios Japan KK.